Table 1.
Patient demographic and baseline characteristics.
| Variables | FAS (N=85) |
|---|---|
| Age (y), median (range) | 31.9 (18, 67) |
| Male sex | 52 (61.2) |
| ECOG performance score | |
| 0 | 63 (74.1) |
| 1 | 22 (25.9) |
| B symptoms | 32 (37.6) |
| Clinical stage | |
| I | 1 (1.2) |
| II | 13 (15.3) |
| III | 16 (18.8) |
| IV | 55 (64.7) |
| Histology | |
| Nodular sclerosing Hodgkin lymphoma (NSHL) | 58 (68.2) |
| Mixed cellularity (MCHL) | 20 (23.5) |
| Lymphocyte-rich classical HL (LRCHL) | 4 (4.7) |
| Unknown | 3 (3.5) |
| Duration from initial diagnosis, median (range) | 24.2 (3.4, 290.7) |
| Bone marrow infiltration | 21 (24.7) |
| Previous chemotherapy | |
| Median (range) lines | 3 (2, 11) |
| ≥3 lines | 45 (52.9) |
| Other previous therapies | |
| Surgery | 7 (8.2) |
| Radiotherapy | 41 (48.2) |
| Autologous hematopoietic stem cell transplant | 14 (16.5) |
| Brentuximab vedotin | 0 |
Data are shown as n (%) unless indicated otherwise.